Gene symbol | APOB | Synonyms | FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 | Type of gene | protein-coding |
Chromosome | 2 | Map location | 2p24.1 | dbXrefs | |
Gene perturbation-related omics dataset | PertOrg | ||||
Description | apolipoprotein B |
GTO ID | GTC1376 |
Trial ID | NCT01299298 |
Disease | Familial Hypercholesterolemia |
Altered gene | APOB |
Therapeutic/Target gene | Target gene |
Therapy | ASO |
Treatment | ISIS 301012|mipomersen sodium|Kynamro |
Location approved | US, Mexico, Argentina, South Korea |
Phase | Phase1 |
Recruitment status | Completed |
Title | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects |
Year | 2011 |
Country | Germany |
Company sponsor | Kastle Therapeutics, LLC |
Other ID(s) | MIPO3700710|2010-021948-18 |
Vector information | |||
|
Cohort1: mipomersen_dose level 1 | |||||||
|
|||||||
Cohort2: mipomersen_dose level 2 | |||||||
|
|||||||
Cohort3: mipomersen_dose level 3 | |||||||
|
|||||||
Cohort4: Placebo | |||||||
|